🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — off 2 antihypertensives

My blood pressure normalization journey — off 2 antihypertensives

BethLabQueen Sat, May 16, 2026 at 5:28 PM 27 replies 640 viewsPage 1 of 6
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 16, 2026 at 5:28 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Relative versus absolute is the distinction that gets lost: a 20% relative reduction on a high baseline risk is a large absolute benefit, and the same relative figure on a low baseline risk is a small one.

The question I want answered is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Tell me what I have not thought of.

1 21maya_sedona
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
May 16, 2026 at 7:44 PM#2
BethLabQueen said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
50 20PharmD_Rodriguez, julia.endo, JessicaM_2024 and 47 others
Reply Quote Save Share Report
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
May 16, 2026 at 10:00 PM#3
LibrarianMeg said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

49 19jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 46 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
May 17, 2026 at 12:16 AM#4
BethLabQueen said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mine went the same way, slower.

Last edited: May 17, 2026 at 2:16 AM
48 18TomFromTexas, mike.trainer_LA, sarah_nash92 and 45 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
May 17, 2026 at 1:48 PM#5

Adding the clinical framing, because it changes how the question reads.

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

15 months later: down 52 lbs, off atorvastatin, A1C from 8.4% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

47 17LabKate, kate.chem, DataDave and 44 others
Reply Quote Save Share Report
1236

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register